Arcutis Biotherapeutics Inc (ARQT)

Mar 31, 2025

Seborrhoeic Dermatitis Market Growth to Accelerate in Forecast - openPR.com

Mar 31, 2025

Mar 31, 2025

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% - MSN

Mar 31, 2025

Mar 30, 2025

Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone - MSN

Mar 30, 2025

Mar 28, 2025

Are Medical Stocks Lagging Cardinal Health (CAH) This Year? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Leading Immuno-Dermatology Player Arcutis Set for Major Investor Presentation at Needham Healthcare - Stock Titan

Mar 27, 2025

Mar 27, 2025

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference - TradingView

Mar 27, 2025

Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock By Investing.com - Investing.com Canada

Mar 26, 2025

Mar 26, 2025

Arcutis Biotherapeutics CEO sells $64,413 in stock - Investing.com

Mar 26, 2025

Mar 26, 2025

Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st

Mar 26, 2025

Mar 25, 2025

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Mar 25, 2025

Mar 24, 2025

Arcutis throws to Odell Beckham Jr., the latest face of Zorvye foam - Medical Marketing and Media

Mar 24, 2025

Mar 24, 2025

Arcutis throws to Odell Beckham Jr., the latest face of Zoryve foam - MM+M Online

Mar 24, 2025

Mar 20, 2025

Arcutis Biotherapeutics shares jump - MSN

Mar 20, 2025

Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 By Investing.com - Investing.com South Africa

Mar 20, 2025

Mar 20, 2025

Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137 - Investing.com India

Mar 20, 2025

Mar 17, 2025

What's Going On With Arcutis Biotherapeutics Stock Monday? - Benzinga

Mar 17, 2025

Mar 17, 2025

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age - Quantisnow

Mar 17, 2025

Mar 17, 2025

Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment - Marketscreener.com

Mar 17, 2025

Mar 12, 2025

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha

Mar 12, 2025

Mar 12, 2025

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World

Mar 12, 2025

Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World

Mar 12, 2025

Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada

Mar 11, 2025

Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 10, 2025

Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR

Mar 10, 2025

Mar 10, 2025

Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World

Mar 10, 2025

Mar 09, 2025

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St

Mar 09, 2025

Mar 07, 2025

Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks

Mar 07, 2025

Mar 07, 2025

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times

Mar 07, 2025

Mar 07, 2025

Arcutis Biotherapeutics Inc (ARQT) Unveils Promising Data on ZORYVE® Cream and Foam at AAD 2025 - GuruFocus.com

Mar 07, 2025

Mar 07, 2025

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... - The Bakersfield Californian

Mar 07, 2025

Mar 07, 2025

Breakthrough Phase 3 Results: New Treatment Shows 97% Success Rate in Major Skin Conditions - StockTitan

Mar 07, 2025

Mar 06, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Yahoo Finance

Mar 06, 2025

Mar 06, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 06, 2025

Mar 05, 2025

Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN

Mar 05, 2025

Mar 05, 2025

Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com

Mar 05, 2025

Mar 05, 2025

Seborrhoeic Dermatitis Clinical and Non-Clinical Studies, Key - openPR

Mar 05, 2025

Mar 05, 2025

Arcutis Biotherapeutics CEO Todd Watanabe sells $327,019 in stock - Investing.com India

Mar 05, 2025

Mar 05, 2025

Arcutis Biotherapeutics (ARQT) – Research Analysts’ Recent Ratings Updates - Defense World

Mar 05, 2025

Mar 04, 2025

Arcutis Biotherapeutics Inc Stock: Executives Sell Shares Following Strong Results - sharewise

Mar 04, 2025

Mar 04, 2025

Arcutis Biotherapeutics director sells $130,048 in stock By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 04, 2025

Arcutis Biotherapeutics executive sells $49,407 in stock By Investing.com - Investing.com South Africa

Mar 04, 2025